Home > Financial Ratios > GLAND PHARMA

GLAND PHARMA
Core EBITDA Growth

    Back to All Ratios
GLAND PHARMA is part of below Screeners ↓
Top Mid Cap Stocks with Best Fundamentals
Best Quarterly Growth Mid Cap Stocks
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results

GLAND PHARMA Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2026Mar2025Mar2024Mar2023Mar2022
   Core EBITDA Growth(%) 31.25-1.3818.82-27.0420.67

What is the latest Core EBITDA Growth ratio of GLAND PHARMA ?

The latest Core EBITDA Growth ratio of GLAND PHARMA is 31.25 based on Mar2026 Consolidated results.
Year Core EBITDA Growth
Mar202631.25
Mar2025-1.38
Mar202418.82
Mar2023-27.04
Mar202220.67

How is Core EBITDA Growth of GLAND PHARMA Trending?

Years Core EBITDA Growth % Change
Mar2026 31.25
Positive
Mar2025 -1.38
Negative
Mar2024 18.82
Positive
Mar2023 -27.04
Negative
Mar2022 20.67 -

Other Financial Ratios of GLAND PHARMA


Compare Core EBITDA Growth ratio of peers of GLAND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLAND PHARMA ₹43,947.8 Cr 0.9% 5.3% 26.7% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹468,530.0 Cr -0.1% 0.5% 14% Stock Analytics
DIVIS LABORATORIES ₹219,675.0 Cr -0.9% 21.1% 25.6% Stock Analytics
TORRENT PHARMACEUTICALS ₹186,970.0 Cr -1.3% 1.1% 32.7% Stock Analytics
CIPLA ₹117,947.0 Cr 0.2% 2.1% -5.1% Stock Analytics
DR REDDYS LABORATORIES ₹96,601.2 Cr 0.2% -7.7% -7.5% Stock Analytics


GLAND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

0.9%

5.3%

26.7%

SENSEX

-0.1%

2.4%

-3.3%


You may also like the below Video Courses